Predictive association of inflammatory MRI and ultrasound scores of patients in clinical remission after 1 year to treatment escalation, radiographic erosive progression and MRI erosive progression during the second year of follow-up, ORs (95% CI)
| Univariate | Multivariate | |||
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Treatment escalation | ||||
| MRI synovitis | 0.90 (0.78 to 1.05) | 0.19 | 0.95 (0.80 to 1.13) | 0.56 |
| MRI tenosynovitis | 1.09 (0.95 to 1.26) | 0.20 | 1.19 (1.01 to 1.41) | 0.04 |
| MRI bone marrow oedema | 0.98 (0.87 to 1.10) | 0.75 | 1.03 (0.90 to 1.18) | 0.65 |
| MRI combined inflammation | 1.00 (0.99 to 1.01) | 0.60 | 1.00 (0.99 to 1.01) | 0.56 |
| Ultrasound grey scale | 1.00 (0.96 to 1.04) | 0.94 | 1.02 (0.97 to 1.08) | 0.41 |
| Ultrasound power Doppler | 1.01 (0.95 to 1.07) | 0.69 | 1.05 (0.98 to 1.13) | 0.18 |
| Radiographic erosive progression | ||||
| MRI synovitis | 1.24 (1.09 to 1.41) | 0.001 | 1.20 (1.03 to 1.40) | 0.02 |
| MRI tenosynovitis | 1.36 (1.15 to 1.62) | <0.001 | 1.29 (1.08 to 1.55) | 0.006 |
| MRI bone marrow oedema | 1.14 (1.03 to 1.27) | 0.01 | 1.06 (0.93 to 1.19) | 0.38 |
| MRI combined inflammation | 1.02 (1.01 to 1.03) | <0.001 | 1.02 (1.01 to 1.03) | 0.004 |
| Ultrasound grey scale | 1.06 (1.01 to 1.11) | 0.03 | 1.05 (1.00 to 1.12) | 0.07 |
| Ultrasound power Doppler | 1.12 (0.98 to 1.28) | 0.09 | 1.12 (0.97 to 1.29) | 0.12 |
| MRI erosive progression | ||||
| MRI synovitis | 1.41 (1.18 to 1.68) | <0.001 | 1.43 (1.13 to 1.80) | 0.003 |
| MRI tenosynovitis | 1.30 (1.10 to 1.53) | 0.002 | 1.26 (1.06 to 1.51) | 0.01 |
| MRI bone marrow oedema | 1.22 (1.08 to 1.38) | 0.001 | 1.18 (1.00 to 1.39) | 0.05 |
| MRI combined inflammation | 1.03 (1.01 to 1.04) | <0.001 | 1.03 (1.01 to 1.05) | 0.001 |
| Ultrasound grey scale | 1.02 (0.98 to 1.07) | 0.30 | 1.01 (0.96 to 1.08) | 0.61 |
| Ultrasound power Doppler | 1.03 (0.96 to 1.09) | 0.44 | 1.02 (0.94 to 1.10) | 0.63 |
Treatment escalation: change to a higher level of therapy during the second year. Radiographic erosive progression: increase ≥1 vdHSS erosion score during second year. MRI erosive progression: increase ≥1 RAMRIS erosion score during second year. Multivariate model adjusted for clinical model predictors age, gender, SJC, RAI, PGA, CRP, ACPA status and radiographic erosions. Estimates of univariate and multivariate associations between the clinical model predictors and the outcomes are shown in online supplemental table S5. P values of <0.05 marked in bold typeface.
ACPA, anti-citrullinated protein antibody; CRP, C reactive protein; PGA, patient global assessment; RAI, Ritchie Articular Index; RAMRIS, rheumatoid arthritis MRI scoring system; SJC, swollen joint count; vdHSS, van der Heijde modified Sharp score.